Anas Younes1, Joshua Brody2, Cecilia Carpio3, Armando Lopez-Guillermo4, Dina Ben-Yehuda5, Burhan Ferhanoglu6, Arnon Nagler7, Muhit Ozcan8, Irit Avivi9, Francesc Bosch3, Maria Dolores Caballero Barrigón10, Andrzej Hellmann11, Bryone Kuss12, David D F Ma13, Fatih Demirkan14, Münci Yağci15, Netanel A Horowitz16, Paula Marlton17, Raul Cordoba18, Tomasz Wrobel19, Daniela Buglio20, Michael Streit21, Brendan P Hodkinson21, Michael Schaffer21, John Alvarez21, Rob Ceulemans22, Sriram Balasubramanian23, Jan de Jong23, Shean-Sheng Wang24, Nele Fourneau22, Wojciech Jurczak25. 1. Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: younesa@mskcc.org. 2. Icahn School of Medicine at Mount Sinai, New York, NY, USA. 3. University Hospital Vall d'Hebron, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. 4. Department of Hematology, Hospital Clínic, Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Barcelona, Spain. 5. Hadassah Medical Center, Hebrew University of Jerusalem, Faculty of Medicine, Jerusalem, Israel. 6. Department of Hematology, Koç University School of Medicine, Istanbul, Turkey. 7. Chaim Sheba Medical Centre, Tel-Hashomer, Israel. 8. Ankara University School of Medicine, Ankara, Turkey. 9. Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 10. Hospital Clínico Universitario de Salamanca, Salamanca, Spain. 11. Medical University of Gdansk, Gdansk, Poland. 12. Flinders Medical Centre and Flinders University, Adelaide, SA, Australia. 13. St Vincent's Hospital, Sydney, NSW, Australia. 14. Dokuz Eylül University, Izmir, Turkey. 15. Gazi University, Ankara, Turkey. 16. Rambam Health Care Campus, Haifa, Israel. 17. Princess Alexandra Hospital, University of Queensland School of Medicine, Brisbane, QLD, Australia. 18. Fundacion Jimenez Diaz University Hospital, Madrid, Spain. 19. Wroclaw Medical University, Wroclaw, Poland. 20. Bristol-Myers Squibb, Lawrenceville, NJ, USA. 21. Janssen R&D, Spring House, PA, USA. 22. Janssen R&D, Beerse, Belgium. 23. Janssen R&D, San Diego, CA, USA. 24. Janssen R&D, Raritan, NJ, USA. 25. Department of Hematology, Jagiellonian University, Krakow, Poland.
Abstract
BACKGROUND: Preclinical studies have shown synergistic antitumour effects between ibrutinib and immune-checkpoint blockade. The aim of this study was to assess the safety and activity of ibrutinib in combination with nivolumab in patients with relapsed or refractory B-cell malignant diseases. METHODS: We did a two-part, open-label, phase 1/2a study at 21 hospitals in Australia, Israel, Poland, Spain, Turkey, and the USA. The primary objective of part A (dose escalation) was to assess the safety of daily oral ibrutinib (420 mg or 560 mg) in combination with intravenous nivolumab (3 mg/kg every 2 weeks) to ascertain a recommended phase 2 dose in patients with relapsed or refractory high-risk chronic lymphocytic leukaemia or small lymphocytic lymphoma (del17p or del11q), follicular lymphoma, or diffuse large B-cell lymphoma. Dose optimisation was investigated using a modified toxicity probability interval design. The primary objective of the part B expansion phase was to establish the preliminary activity (the proportion of patients who achieved an overall response) of the combination of ibrutinib and nivolumab in four cohorts: relapsed or refractory high-risk chronic lymphocytic leukaemia or small lymphocytic lymphoma (del17p or del11q), follicular lymphoma, diffuse large B-cell lymphoma, and Richter's transformation. All participants who received at least one dose of treatment were included in the primary analysis and analyses were done by disease cohort. This trial is registered with ClinicalTrials.gov, number NCT02329847. The trial is ongoing. FINDINGS: Between March 12, 2015, and April 11, 2017, 144 patients were enrolled in the study. Three patients died before receiving study treatment; thus, 141 patients were included in the analysis, 14 in part A and 127 in part B. One dose-limiting toxicity (grade 3 hyperbilirubinaemia) was reported at the 420 mg dose in the diffuse large B-cell lymphoma cohort, which resolved after 5 days. The combination of ibrutinib and nivolumab led to overall responses in 22 (61%) of 36 patients with high-risk chronic lymphocytic leukaemia or small lymphocytic lymphoma, 13 (33%) of 40 patients with follicular lymphoma, 16 (36%) of 45 patients with diffuse large B-cell lymphoma, and 13 (65%) of 20 patients with Richter's transformation. The most common all-grade adverse events were diarrhoea (47 [33%] of 141 patients), neutropenia (44 [31%]), and fatigue (37 [26%]). 11 (8%) of 141 patients had adverse events leading to death; none were reported as drug-related. The most common grade 3-4 adverse events were neutropenia (40 [28%] of 141 patients) and anaemia (32 [23%]). The incidence of grade 3-4 neutropenia ranged from eight (18%) of 45 patients with diffuse large B-cell lymphoma to 19 (53%) of 36 patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma; incidence of grade 3-4 anaemia ranged from five (13%) of 40 patients with follicular lymphoma to seven (35%) of 20 patients with Richter's transformation. The most common serious adverse events included anaemia (six [4%] of 141 patients) and pneumonia (five [4%]). The most common grade 3-4 immune-related adverse events were rash (11 [8%] of 141 patients) and increased alanine aminotransferase (three [2%]). INTERPRETATION: The combination of ibrutinib and nivolumab had an acceptable safety profile and preliminary activity was similar to that reported with single-agent ibrutinib in chronic lymphocytic leukaemia or small lymphocytic lymphoma, follicular lymphoma, and diffuse large B-cell lymphoma. The clinical response in patients with Richter's transformation was promising and supports further clinical assessment. FUNDING: Janssen R&D.
BACKGROUND: Preclinical studies have shown synergistic antitumour effects between ibrutinib and immune-checkpoint blockade. The aim of this study was to assess the safety and activity of ibrutinib in combination with nivolumab in patients with relapsed or refractory B-cell malignant diseases. METHODS: We did a two-part, open-label, phase 1/2a study at 21 hospitals in Australia, Israel, Poland, Spain, Turkey, and the USA. The primary objective of part A (dose escalation) was to assess the safety of daily oral ibrutinib (420 mg or 560 mg) in combination with intravenous nivolumab (3 mg/kg every 2 weeks) to ascertain a recommended phase 2 dose in patients with relapsed or refractory high-risk chronic lymphocytic leukaemia or small lymphocytic lymphoma (del17p or del11q), follicular lymphoma, or diffuse large B-cell lymphoma. Dose optimisation was investigated using a modified toxicity probability interval design. The primary objective of the part B expansion phase was to establish the preliminary activity (the proportion of patients who achieved an overall response) of the combination of ibrutinib and nivolumab in four cohorts: relapsed or refractory high-risk chronic lymphocytic leukaemia or small lymphocytic lymphoma (del17p or del11q), follicular lymphoma, diffuse large B-cell lymphoma, and Richter's transformation. All participants who received at least one dose of treatment were included in the primary analysis and analyses were done by disease cohort. This trial is registered with ClinicalTrials.gov, number NCT02329847. The trial is ongoing. FINDINGS: Between March 12, 2015, and April 11, 2017, 144 patients were enrolled in the study. Three patients died before receiving study treatment; thus, 141 patients were included in the analysis, 14 in part A and 127 in part B. One dose-limiting toxicity (grade 3 hyperbilirubinaemia) was reported at the 420 mg dose in the diffuse large B-cell lymphoma cohort, which resolved after 5 days. The combination of ibrutinib and nivolumab led to overall responses in 22 (61%) of 36 patients with high-risk chronic lymphocytic leukaemia or small lymphocytic lymphoma, 13 (33%) of 40 patients with follicular lymphoma, 16 (36%) of 45 patients with diffuse large B-cell lymphoma, and 13 (65%) of 20 patients with Richter's transformation. The most common all-grade adverse events were diarrhoea (47 [33%] of 141 patients), neutropenia (44 [31%]), and fatigue (37 [26%]). 11 (8%) of 141 patients had adverse events leading to death; none were reported as drug-related. The most common grade 3-4 adverse events were neutropenia (40 [28%] of 141 patients) and anaemia (32 [23%]). The incidence of grade 3-4 neutropenia ranged from eight (18%) of 45 patients with diffuse large B-cell lymphoma to 19 (53%) of 36 patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma; incidence of grade 3-4 anaemia ranged from five (13%) of 40 patients with follicular lymphoma to seven (35%) of 20 patients with Richter's transformation. The most common serious adverse events included anaemia (six [4%] of 141 patients) and pneumonia (five [4%]). The most common grade 3-4 immune-related adverse events were rash (11 [8%] of 141 patients) and increased alanine aminotransferase (three [2%]). INTERPRETATION: The combination of ibrutinib and nivolumab had an acceptable safety profile and preliminary activity was similar to that reported with single-agent ibrutinib in chronic lymphocytic leukaemia or small lymphocytic lymphoma, follicular lymphoma, and diffuse large B-cell lymphoma. The clinical response in patients with Richter's transformation was promising and supports further clinical assessment. FUNDING: Janssen R&D.
Authors: I Landego; D Hewitt; I Hibbert; D Dhaliwal; W Pieterse; D Grenier; R Wong; J Johnston; V Banerji Journal: Curr Oncol Date: 2020-06-01 Impact factor: 3.677
Authors: Philip A Thompson; Xianli Jiang; Pinaki Banerjee; Rafet Basar; Naveen Garg; Ken Chen; Mecit Kaplan; Vandana Nandivada; Ana Karen Nunez Cortes; Alessandra Ferrajoli; Michael J Keating; Christine B Peterson; Michael Andreeff; Katayoun Rezvani; William G Wierda Journal: Leukemia Date: 2022-08-08 Impact factor: 12.883
Authors: Tiziana Vaisitti; Francesca Arruga; Nicoletta Vitale; Thanh-Trang Lee; Mira Ko; Amy Chadburn; Esteban Braggio; Arianna Di Napoli; Andrea Iannello; John N Allan; Langdon L Miller; Brian J Lannutti; Richard R Furman; Katti A Jessen; Silvia Deaglio Journal: Blood Date: 2021-06-17 Impact factor: 22.113
Authors: Paolo Sportoletti; Filomena De Falco; Beatrice Del Papa; Stefano Baldoni; Valerio Guarente; Andrea Marra; Erica Dorillo; Chiara Rompietti; Francesco Maria Adamo; Loredana Ruggeri; Mauro Di Ianni; Emanuela Rosati Journal: Int J Mol Sci Date: 2021-06-22 Impact factor: 5.923